SR13904

peroxisome proliferator-activated receptor delta antagonist with anti-proliferative activity in human cancer cells; structure in first source

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Lung Neoplasms (Lung Cancer) 07/01/2009 - "Molecular studies show that SR13904 treatment of a lung cancer cell line, A549, results in markedly reduced levels of a number of cell cycle proteins including cyclin A and D, and cyclin dependent kinase (CDK) 2 and 4. The inhibitory effects on CDK2 appear to be transcriptional. "
2.	Carcinogenesis 07/01/2009 - "The antitumor activities of SR13904 suggest that antagonism of PPARdelta-mediated transactivation may inhibit tumorigenesis and that pharmacological inhibition of PPARdelta may be a potential strategy for treatment or prevention of cancer."
3.	Neoplasms (Cancer) 07/01/2009 - "These inhibitory effects of SR13904 on tumor cells were linked to a G(1)/S cell cycle block and increased apoptosis. " 07/01/2009 - "A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells." 07/01/2009 - "The antitumor activities of SR13904 suggest that antagonism of PPARdelta-mediated transactivation may inhibit tumorigenesis and that pharmacological inhibition of PPARdelta may be a potential strategy for treatment or prevention of cancer."
4.	Carcinoma (Carcinomatosis) 07/01/2009 - "SR13904 displays inhibitory effects on cellular proliferation and survival in several human carcinoma lines, including lung, breast and liver. "

1.	Cyclin A
2.	Cyclin-Dependent Kinases (cdk Proteins)
3.	Cell Cycle Proteins
4.	PPAR delta